Key facts
- Biosphere (Pharmaceuticals and Biotechnology)’s last known valuation is $15.0M (Jan 2023).
- It has raised $13.8M; the latest was Seed Round ($8.8M) in Jan 2025.
- Notable investors include Founders Fund, Caffeinated Capital, Lowercarbon Capital, GS Futures, Also Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Biosphere (Pharmaceuticals and Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosphere (Pharmaceuticals and Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosphere (Pharmaceuticals and Biotechnology)
Developer of a modern biomanufacturing platform intended to enhance the efficiency of producing various biological materials. The company offers a UV-enabled bioreactor design that significantly reduces capital intensity and supports the production of therapeutics, enzymes, proteins, bioplastics, fertilizers and jet fuel, enabling industries to achieve sustainable material abundance while addressing the growing demand for biological products in a resource-constrained world.
- Sector
- Healthcare
- HQ
- Oakland, CA, United States
- Founded
- 2022
- Employees
- 18
- Website
- biosphere.io/
- Ownership
- Privately Held (backing)
Biosphere (Pharmaceuticals and Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosphere (Pharmaceuticals and Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosphere (Pharmaceuticals and Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.